Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/14/26 Johnson & Johnson (JNJ) Tecvayli for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
6/14/26 Bristol Myers Squibb (BMY) Revlimid for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
6/14/26 Eli Lilly and Company (LLY) Jaypirca for Non-Hodgkin's Lymphoma (NHL) Subscribers Only Subscribers Only Subscribers Only
6/14/26 Eli Lilly and Company (LLY) Jaypirca for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) Subscribers Only Subscribers Only Subscribers Only
6/13/26 Johnson & Johnson (JNJ) Darzalex Faspro for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/31/2023 Subscribers Only Subscribers Only Trial Announcement - Initiation
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update